JO
EIDX

John Overdeck’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

John Overdeck’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,997
Closed -$344K – 4083
2019
Q4 		$344K Buy
+5,997
New +$297K ﹤0.01% 3083
2018
Q4 		– Sell
-10,418
Closed -$104K – 3708
2018
Q3 		$104K Buy
+10,418
New +$171K ﹤0.01% 3075

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

John Overdeck's EIDX Position: Q1 2020 in Review

John Overdeck sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 5,997 shares — an estimated $344K sold.

John Overdeck first reported a position in EIDX in Q3 2018 and held it in 2 quarters. The position peaked at $344K in Q4 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

  • John Overdeck reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • John Overdeck sold 5,997 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $344K.
  • John Overdeck first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • John Overdeck's Eidos Therapeutics, Inc. Common Stock position peaked at $344K in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Two Sigma Investments's 13F filing for Q1 2020, filed 15 May 2020.